Related Experiment Video
Updated: Oct 23, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve
Carmelo J Blanquicett1, Luis E Aguirre1
1Departments of Hematology and Oncology, Moffitt Cancer Center, Tampa, Fl, USA.
Abstract:
Despite precision medicine and advances in oncology such as immunotherapy and targeted therapy that have made substantial strides in certain solid malignancies, effective treatment options are still needed for pancreatic cancer, a highly-lethal disease with a dismal prognosis. Current treatment regimens with antimetabolites and taxanes have only modestly improved survival rates, and surgery remains the only curative measure, with just a minority of patients being eligible for curative surgery at the time of diagnosis. The role of traditional anti-cancer approaches such as radiation has yet to be definitively determined for this malignancy, and more contemporary approaches such as targeted therapy are limited in pancreatic cancer. Exploring alternate expression pathways that can be selectively targeted along with the combination of existing strategies with checkpoint inhibition or CAR-T technology, for example, may prove to be successful in making significant headway for this disease.
Insights
Effective treatments for pancreatic cancer are lacking. New strategies combining targeted therapies with immunotherapy, like checkpoint inhibition or CAR-T technology, show promise for improving survival in this lethal disease.
Area of Science:
- Oncology
- Cancer Research
- Precision Medicine
Background:
- Pancreatic cancer remains a highly lethal disease with a poor prognosis.
- Current treatments, including chemotherapy and surgery, offer limited survival benefits.
- Effective therapeutic strategies for pancreatic cancer are urgently needed.
Purpose of the Study:
- To review the current landscape of pancreatic cancer treatment.
- To explore novel therapeutic avenues and combinations for pancreatic cancer.
- To identify potential targets for improving patient outcomes.
Main Methods:
- Review of existing literature on pancreatic cancer therapies.
- Analysis of limitations of current treatment modalities.
- Exploration of emerging therapeutic strategies, including targeted therapy, immunotherapy, and CAR-T technology.
Main Results:
- Conventional treatments like antimetabolites and taxanes provide only modest survival improvements.
- Surgery is the only curative option but is only feasible for a small subset of patients.
- The efficacy of radiation therapy is not yet fully established for pancreatic cancer.
Conclusions:
- Targeted therapies are currently limited in pancreatic cancer.
- Exploring novel expression pathways and combining existing strategies with immunotherapy (e.g., checkpoint inhibition, CAR-T) may offer new hope.
- Further research into combination therapies is crucial for advancing pancreatic cancer treatment.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy